Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential High Dose Testosterone and Enzalutamide vs Enzalutamide Alone in mCRPC
NCT04363164Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2020
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of testosterone cypionate in castration-resistant prostate cancer (CRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2020; status: recruiting.
02
Drugs
testosterone cypionate
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04363164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04363164.